2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reduction
2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalization
2022
Asthma exacerbations during the pandemic: Time to rethink clinical markers
Ortega H, Katz L, Chupp G. Asthma exacerbations during the pandemic: Time to rethink clinical markers. Journal Of Allergy And Clinical Immunology Global 2022, 2: 97-100. PMID: 36281240, PMCID: PMC9581642, DOI: 10.1016/j.jacig.2022.09.003.Peer-Reviewed Original ResearchPrimary end pointAsthma exacerbationsClinical studiesClinical markersEnd pointCOVID-19 pandemicClinical trial enrollmentCoronavirus disease 2019 (COVID-19) pandemicNitric oxide levelsRecent clinical reportsDisease 2019 pandemicPrior exacerbationsPlacebo armFuture exacerbationsTrial enrollmentClinical trialsOxide levelsExacerbationClinical reportsClinical practiceCOVID-19Prior yearPandemicEnrollmentBest predictor
2011
Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood
Bjornsdottir US, Holgate ST, Reddy PS, Hill AA, McKee CM, Csimma CI, Weaver AA, Legault HM, Small CG, Ramsey RC, Ellis DK, Burke CM, Thompson PJ, Howarth PH, Wardlaw AJ, Bardin PG, Bernstein DI, Irving LB, Chupp GL, Bensch GW, Bensch GW, Stahlman JE, Karetzky M, Baker JW, Miller RL, Goodman BH, Raible DG, Goldman SJ, Miller DK, Ryan JL, Dorner AJ, Immermann FW, O'Toole M. Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood. PLOS ONE 2011, 6: e21902. PMID: 21779351, PMCID: PMC3136489, DOI: 10.1371/journal.pone.0021902.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAsthma exacerbationsBlood mononuclear cellsMononuclear cellsAnalysis of PBMCsAntigen-independent T-cell activationMajor unmet clinical needHuman asthma exacerbationsBronchoalveolar lavage samplesUnmet clinical needT cell activationStable asthmaExacerbation episodesGene expression signaturesRespiratory infectionsAirway tissueLavage samplesAdaptive immunityExacerbationAnalysis of covarianceCell activationInnate immunityLymphocyte activationLevel of expressionClinical need
2009
Intensive Care Unit Management of Status Asthmaticus
Marshall P, Possick J, Chupp G. Intensive Care Unit Management of Status Asthmaticus. Clinical Pulmonary Medicine 2009, 16: 293-301. DOI: 10.1097/cpm.0b013e3181bdff38.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSevere asthma exacerbationsNear-fatal asthmaStatus asthmaticusMechanical ventilationAsthma exacerbationsExtrinsic positive end-expiratory pressureIntensive care unit managementPositive end-expiratory pressureEmergency department visitsNoninvasive mechanical ventilationSubset of patientsEnd-expiratory pressureTypical risk factorsHigh-risk populationRisk of barotraumaUse of sedativesSevere exacerbationsICU admissionSevere asthmaPermissive hypercapniaSystemic therapyDepartment visitsHospital admissionExpiratory pressureRisk stratification